{"task_type": "syndrome_overview", "query": "Explain Community Acquired Pneumonia (CAP) treatment", "response": "# Community Acquired Pneumonia (CAP)\n\n**Definition:** Pneumonia acquired outside of hospitals or other healthcare facilities\n\n**Common Pathogens:**\n- Streptococcus pneumoniae\n- Haemophilus influenzae\n\n**First-Line Treatment (ICMR 2025):**\n- PIPERACILLIN-TAZOBACTAM 4.5g for 7 days\n- AZITHROMYCIN 500mg for 7 days\n- DOXYCYCLINE 100mg for 7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Community Acquired Pneumonia (CAP)", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "How do I treat Staphylococcus spp. infections?", "response": "**Staphylococcus spp.** is commonly associated with:\n\n- Skin and Soft Tissue Infections\n\n**Effective antibiotics include:**\n- AMOXICILLIN-CLAVULANATE\n- BACITRACIN\n- AMOXICILLIN\n- CEPHALEXIN\n- MUPIROCIN\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Staphylococcus spp.", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Tell me about CSF shunt infections", "response": "# CSF shunt infections\n\n**Definition:** For confirmed shunt infections, the shunt should be removed and a temporary external ventricular drain inserted. The shunt should be sent for cultures.\n\n**First-Line Treatment (ICMR 2025):**\n- Vancomycin 25 mg/kg\n- Ceftazidime 2g\n- Cefepime 2g\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "CSF shunt infections", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What antibiotics are recommended for Rhinitis/Common cold?", "response": "According to ICMR 2025 Guidelines for Rhinitis/Common cold:\n\n**First-Line Treatment:**\n- paracetamol\n- Oseltamivir 75mg for 5-7 days\n\n**Alternative Options:**\n- decongestants\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Rhinitis/Common cold", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What does ICMR recommend for treating CSF Shunt Infections?", "response": "According to ICMR 2025 Guidelines for CSF Shunt Infections:\n\n**First-Line Treatment:**\n- Vancomycin 25 mg/kg (IV) for q 8-12h\n- Ceftazidime 2g (IV)\n- Cefepime 2g (IV)\n\n**Alternative Options:**\n- Meropenem\n- Ceftazidime\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "CSF Shunt Infections", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What does ICMR recommend for treating Skin and Soft Tissue Infections?", "response": "According to ICMR 2025 Guidelines for Skin and Soft Tissue Infections:\n\n**First-Line Treatment:**\n- AMOXICILLIN-CLAVULANATE 625mg (PO) for 3 to 7 days\n- AMOXICILLIN-CLAVULANIC ACID 1.2g (IV) for 3 to 7 days\n\n**Alternative Options:**\n- CEFUROXIME\n- CLINDAMYCIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Skin and Soft Tissue Infections", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "In which infections is Cefuroxime used?", "response": "**Cefuroxime** is used in the treatment of:\n\n- Diabetic foot infections (DFI)\n- Acute Osteomyelitis\n- Community Acquired Pneumonia\n- Bite wound infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Cefuroxime", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "What should I know about Febrile neutropenia syndrome?", "response": "# Febrile neutropenia syndrome\n\n**Definition:** Fever in a patient with neutropenia\n\n**First-Line Treatment (ICMR 2025):**\n- Piperacillin-tazobactam 4.5g\n- Cefoperazone-sulbactam 3g\n- Meropenem 1g\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Febrile neutropenia syndrome", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "What is CLINDAMYCIN used for?", "response": "**CLINDAMYCIN** is used in the treatment of:\n\n- Septic Abortion\n- Acute Prostatitis\n- Skin and Soft Tissue Infections\n- Periocular infections (Eyelid infections, Orbital cellulitis)\n- Orbital Cellulitis and Retinitis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "CLINDAMYCIN", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Give me an overview of Tertiary Peritonitis", "response": "# Tertiary Peritonitis\n\n**Definition:** A type of intra-abdominal infection, specifically healthcare-associated infection\n\n**First-Line Treatment (ICMR 2025):**\n- IMIPENEM-CILASTATIN 500 mg for 5-7 days\n- MEROPENEM 1g for 5-7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Tertiary Peritonitis", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "Show me the treatment guidelines for Febrile neutropenia syndrome", "response": "According to ICMR 2025 Guidelines for Febrile neutropenia syndrome:\n\n**First-Line Treatment:**\n- Piperacillin-tazobactam 4.5g (IV)\n- Cefoperazone-sulbactam 3g (IV)\n- Meropenem 1g (IV)\n\n**Alternative Options:**\n- Meropenem\n- Imipenem\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Febrile neutropenia syndrome", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What does ICMR recommend for treating Antibiotic Associated Diarrhoea?", "response": "According to ICMR 2025 Guidelines for Antibiotic Associated Diarrhoea:\n\n**First-Line Treatment:**\n- VANCOMYCIN 125mg (PO) for Not specified\n- METRONIDAZOLE 500mg (IV) for Not specified\n\n**Common Pathogens:** Clostridium difficile\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Antibiotic Associated Diarrhoea", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What antibiotics are recommended for Burn wound infections?", "response": "According to ICMR 2025 Guidelines for Burn wound infections:\n\n**First-Line Treatment:**\n- Silver sulfadiazine 1% (Topical)\n- Silver nitrate 0.5% (Topical)\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Burn wound infections", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Explain Infections of Liver, Gall Bladder and Biliary tract treatment", "response": "# Infections of Liver, Gall Bladder and Biliary tract\n\n**Definition:** Infections of Liver, Gall Bladder and Biliary tract\n\n**First-Line Treatment (ICMR 2025):**\n- Metronidazole 750mg for total 10 days\n- Ceftriaxone 2g\n- Metronidazole 750mg\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Infections of Liver, Gall Bladder and Biliary tract", "source": "ICMR 2025"}
{"task_type": "education", "query": "Why is antibiotic resistance a problem?", "response": "Antibiotic resistance is a major global health threat because:\n\n1. **Treatment failures**: Infections become harder or impossible to treat\n2. **Increased mortality**: Resistant infections lead to more deaths\n3. **Longer hospitalizations**: Patients require extended care\n4. **Higher healthcare costs**: More expensive drugs and procedures needed\n5. **Limited options**: Fewer effective antibiotics available\n6. **Spread of resistance**: Resistant genes can transfer between bacteria\n\nRational antibiotic use and adherence to guidelines like ICMR 2025 help combat resistance.", "source": "AMR education"}
{"task_type": "guideline_lookup", "query": "What does ICMR recommend for treating Possible serious bacterial infection, PSBI (community acquired)?", "response": "According to ICMR 2025 Guidelines for Possible serious bacterial infection, PSBI (community acquired):\n\n**First-Line Treatment:**\n- Amoxicillin 20-40 mg/kg/dose (PO)\n- Ampicillin 50 mg/kg/dose (IV)\n- Ampicillin 75 mg/kg/dose (IV)\n\n**Alternative Options:**\n- Ampicillin\n- Cefotaxime\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Possible serious bacterial infection, PSBI (community acquired)", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "Show me the treatment guidelines for Invasive Candidiasis", "response": "According to ICMR 2025 Guidelines for Invasive Candidiasis:\n\n**First-Line Treatment:**\n- Micafungin 100 mg (IV)\n- Anidulafungin 200 mg (IV)\n- Caspofungin 70 mg (IV)\n\n**Alternative Options:**\n- Liposomal Amphotericin B\n\n**Common Pathogens:** Candida albicans, C. glabrata, C. parapsilosis\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Invasive Candidiasis", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What is the first-line treatment for Tertiary Peritonitis?", "response": "According to ICMR 2025 Guidelines for Tertiary Peritonitis:\n\n**First-Line Treatment:**\n- IMIPENEM-CILASTATIN 500 mg (IV) for 5-7 days\n- MEROPENEM 1g (IV) for 5-7 days\n\n**Alternative Options:**\n- POLYMYXIN B\n- COLISTIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Tertiary Peritonitis", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "What should I know about Enteric fever?", "response": "# Enteric fever\n\n**Definition:** Blood culture remains the gold standard.\n\n**First-Line Treatment (ICMR 2025):**\n- Azithromycin 20 mg /kg/day for 7 days\n- Cotrimoxazole 960 mg for 2 weeks\n- Ceftriaxone 2g for 10-14 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Enteric fever", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Explain Conjunctivitis treatment", "response": "# Conjunctivitis\n\n**Definition:** Infection of the conjunctiva, can be bacterial or viral\n\n**Common Pathogens:**\n- HSV\n- Adenovirus\n- CMV\n\n**First-Line Treatment (ICMR 2025):**\n- TOBRAMYCIN Not specified for 7 days\n- GENTAMICIN Not specified for 7 days\n- ACYCLOVIR 20 mg/kg/dose for 14 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Conjunctivitis", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "Show me the treatment guidelines for Bronchitis", "response": "According to ICMR 2025 Guidelines for Bronchitis:\n\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Bronchitis", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What antibiotics are recommended for Invasive Candidiasis?", "response": "According to ICMR 2025 Guidelines for Invasive Candidiasis:\n\n**First-Line Treatment:**\n- Micafungin 100 mg (IV)\n- Anidulafungin 200 mg (IV)\n- Caspofungin 70 mg (IV)\n\n**Alternative Options:**\n- Liposomal Amphotericin B\n\n**Common Pathogens:** Candida albicans, C. glabrata, C. parapsilosis\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Invasive Candidiasis", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Tell me about Rhinitis/Common cold", "response": "# Rhinitis/Common cold\n\n**Definition:** Viral rhinitis\n\n**First-Line Treatment (ICMR 2025):**\n- paracetamol\n- Oseltamivir 75mg for 5-7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Rhinitis/Common cold", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Give me an overview of Botulism", "response": "# Botulism\n\n**Definition:** Botulism is a serious medical emergency that requires immediate treatment. Botulinum antitoxins to be administered as soon as possible, this can neutralize botulinum toxin and prevent further damage.\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Botulism", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "When should I prescribe Teicoplanin?", "response": "**Teicoplanin** is used in the treatment of:\n\n- Central Line-Associated Bloodstream Infection (CLABSI)\n- Infective Endocarditis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Teicoplanin", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Give me an overview of Urinary Tract Infections", "response": "# Urinary Tract Infections\n\n**Definition:** Infections involving the urinary system, including cystitis and pyelonephritis, characterized by symptoms such as dysuria, frequency, urgency, and fever\n\n**First-Line Treatment (ICMR 2025):**\n- NITROFURANTOIN 100 mg for 5 days\n- PIPERACILLIN-TAZOBACTAM 4.5g for 7-10 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Urinary Tract Infections", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "What is ANIDULAFUNGIN used for?", "response": "**ANIDULAFUNGIN** is used in the treatment of:\n\n- Healthcare Associated Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "ANIDULAFUNGIN", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What antibiotics are recommended for Febrile neutropenia syndrome?", "response": "According to ICMR 2025 Guidelines for Febrile neutropenia syndrome:\n\n**First-Line Treatment:**\n- Piperacillin-tazobactam 4.5g (IV)\n- Cefoperazone-sulbactam 3g (IV)\n- Meropenem 1g (IV)\n\n**Alternative Options:**\n- Meropenem\n- Imipenem\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Febrile neutropenia syndrome", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "What should I know about Acute Gastroenteritis?", "response": "# Acute Gastroenteritis\n\n**Definition:** Mostly caused by viruses or self-limiting bacterial pathogens.\n\n**First-Line Treatment (ICMR 2025):**\n- Azithromycin 500mg for 3 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Acute Gastroenteritis", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "When should I prescribe Amoxicillin-Clavulanic acid?", "response": "**Amoxicillin-Clavulanic acid** is used in the treatment of:\n\n- Bite wound infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Amoxicillin-Clavulanic acid", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "How do I treat Pseudomonas aeruginosa infections?", "response": "**Pseudomonas aeruginosa** is commonly associated with:\n\n- Acute Osteomyelitis\n\n**Effective antibiotics include:**\n- Cloxacillin\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Pseudomonas aeruginosa", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Explain Neonatal Infections treatment", "response": "# Neonatal Infections\n\n**Definition:** Infections in neonates, including those with specific gestational age and postnatal age considerations\n\n**First-Line Treatment (ICMR 2025):**\n- PIPERACILLIN-TAZOBACTAM 15 mg/kg/dose for 5-7 days or 7-14 days\n- CIPROFLOXACIN 10 mg/kg/dose for 5-7 days or 7-14 days\n- CEFOTAXIME Not specified for 21 days\n\n**Special Populations:** Consider dose adjustments or alternative agents\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Neonatal Infections", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What is the first-line treatment for Encephalitis syndrome?", "response": "According to ICMR 2025 Guidelines for Encephalitis syndrome:\n\n**First-Line Treatment:**\n- Acyclovir 10 mg/kg (IV) for 14-21 days\n- Ceftriaxone 2g (IV)\n- Doxycycline 100mg (PO/IV) for 10-14 days\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Encephalitis syndrome", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Give me an overview of Skin and Soft Tissue Infections", "response": "# Skin and Soft Tissue Infections\n\n**Definition:** Infections involving clean incised wounds, contused lacerated wounds, and contaminated wounds\n\n**First-Line Treatment (ICMR 2025):**\n- AMOXICILLIN-CLAVULANATE 625mg for 3 to 7 days\n- AMOXICILLIN-CLAVULANIC ACID 1.2g for 3 to 7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Skin and Soft Tissue Infections", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "What is Penicillin G used for?", "response": "**Penicillin G** is used in the treatment of:\n\n- Infective Endocarditis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Penicillin G", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "Tell me about COLISTIN", "response": "**COLISTIN** is used in the treatment of:\n\n- Healthcare Associated Infections\n- Tertiary Peritonitis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "COLISTIN", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Explain Bronchitis treatment", "response": "# Bronchitis\n\n**Definition:** Bronchitis\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Bronchitis", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "What antibiotics work against Mycobacterium tuberculosis?", "response": "**Mycobacterium tuberculosis** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Mycobacterium tuberculosis", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What antibiotics are recommended for Acute Undifferentiated Febrile illness?", "response": "According to ICMR 2025 Guidelines for Acute Undifferentiated Febrile illness:\n\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Acute Undifferentiated Febrile illness", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "What antibiotics work against Gram Negative bacilli?", "response": "**Gram Negative bacilli** is commonly associated with:\n\n- Periocular infections (Eyelid infections, Orbital cellulitis)\n\n**Effective antibiotics include:**\n- AMOXICILLIN-CLAVULANATE\n- CEFTRIAXONE\n- AMOXICILLIN\n- CLINDAMYCIN\n- COTRIMOXAZOLE\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Gram Negative bacilli", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "In which infections is Ceftazidime-avibactam used?", "response": "**Ceftazidime-avibactam** is used in the treatment of:\n\n- Febrile neutropenia syndrome\n- Febrile neutropenia syndrome\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Ceftazidime-avibactam", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "List the first-line drugs for Infective Endocarditis", "response": "According to ICMR 2025 Guidelines for Infective Endocarditis:\n\n**First-Line Treatment:**\n- Penicillin G 4 million units (IV) for 4 weeks\n- Ampicillin 2g (IV) for 4 weeks\n- Gentamicin 1mg/kg (IM or IV) for first 2 weeks\n\n**Alternative Options:**\n- Vancomycin\n- Gentamicin\n\n**Common Pathogens:** Staphylococcus aureus, Coagulase-negative Staphylococci, Enterococci\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Infective Endocarditis", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "List the first-line drugs for Antimicrobial Treatment Guidelines", "response": "According to ICMR 2025 Guidelines for Antimicrobial Treatment Guidelines:\n\n**First-Line Treatment:**\n- MEROPENEM 1g (IV) for Not specified\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Antimicrobial Treatment Guidelines", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "What drugs are effective for Vibrio spp.?", "response": "**Vibrio spp.** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Vibrio spp.", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "Show me the treatment guidelines for Febrile neutropenia syndrome", "response": "According to ICMR 2025 Guidelines for Febrile neutropenia syndrome:\n\n**First-Line Treatment:**\n- Piperacillin-tazobactam 4.5g (IV)\n- Cefoperazone-sulbactam 3g (IV)\n- Meropenem 1g (IV)\n\n**Alternative Options:**\n- Meropenem\n- Imipenem\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Febrile neutropenia syndrome", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "Tell me about Streptococcus pneumoniae treatment", "response": "**Streptococcus pneumoniae** is commonly associated with:\n\n- Periocular infections (Eyelid infections, Orbital cellulitis)\n- Community Acquired Pneumonia (CAP)\n\n**Effective antibiotics include:**\n- AMOXICILLIN-CLAVULANATE\n- AZITHROMYCIN\n- CEFTRIAXONE\n- PIPERACILLIN-TAZOBACTAM\n- AMOXICILLIN\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Streptococcus pneumoniae", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "What should I know about Community Acquired Pneumonia (CAP)?", "response": "# Community Acquired Pneumonia (CAP)\n\n**Definition:** Pneumonia acquired outside of hospitals or other healthcare facilities\n\n**Common Pathogens:**\n- Streptococcus pneumoniae\n- Haemophilus influenzae\n\n**First-Line Treatment (ICMR 2025):**\n- PIPERACILLIN-TAZOBACTAM 4.5g for 7 days\n- AZITHROMYCIN 500mg for 7 days\n- DOXYCYCLINE 100mg for 7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Community Acquired Pneumonia (CAP)", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "In which infections is Tinidazole used?", "response": "**Tinidazole** is used in the treatment of:\n\n- Infections of Liver, Gall Bladder and Biliary tract\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Tinidazole", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "In which infections is Polymyxin B used?", "response": "**Polymyxin B** is used in the treatment of:\n\n- Febrile neutropenia syndrome\n- Febrile neutropenia syndrome\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Polymyxin B", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Explain Bite wound infections treatment", "response": "# Bite wound infections\n\n**Definition:** Wound infections caused by animal (dog/cat/monkey/human) bites.\n\n**Common Pathogens:**\n- Staphylococcus aureus\n- Pasteurella multocida\n- Anaerobes\n- Capnocytophaga canimorsus\n- Viridans streptococci\n\n**First-Line Treatment (ICMR 2025):**\n- Amoxicillin-clavulanic acid 625mg for 3 to 5 days\n- Piperacillin-tazobactam 4.5g for 5 to 7 days\n- Valacyclovir/Acyclovir for 7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Bite wound infections", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Explain Infective Endocarditis treatment", "response": "# Infective Endocarditis\n\n**Definition:** Infection of the heart valves, typically requiring empirical antibiotic therapy pending blood culture results\n\n**First-Line Treatment (ICMR 2025):**\n- PENICILLIN G 4 million units for 4 weeks\n- AMPICILLIN 2g for 4 weeks\n- VANCOMYCIN 15mg/kg for 4-6 weeks\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Infective Endocarditis", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "Tell me about Staphylococcus aureus treatment", "response": "**Staphylococcus aureus** is commonly associated with:\n\n- Acute Osteomyelitis\n- Periocular infections (Eyelid infections, Orbital cellulitis)\n- Bite wound infections\n\n**Effective antibiotics include:**\n- AMOXICILLIN-CLAVULANATE\n- Amoxicillin-Clavulanic acid\n- CEFTRIAXONE\n- AMOXICILLIN\n- Amoxicillin-clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Staphylococcus aureus", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "In which infections is CEFUROXIME used?", "response": "**CEFUROXIME** is used in the treatment of:\n\n- Skin and Soft Tissue Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "CEFUROXIME", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "How do I treat Viridans streptococci infections?", "response": "**Viridans streptococci** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Viridans streptococci", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "Tell me about TRIFLURIDINE", "response": "**TRIFLURIDINE** is used in the treatment of:\n\n- Conjunctivitis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "TRIFLURIDINE", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "How do I treat Escherichia coli infections?", "response": "**Escherichia coli** is commonly associated with:\n\n- Acute Osteomyelitis\n\n**Effective antibiotics include:**\n- Cloxacillin\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Escherichia coli", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What is the first-line treatment for Febrile neutropenia syndrome?", "response": "According to ICMR 2025 Guidelines for Febrile neutropenia syndrome:\n\n**First-Line Treatment:**\n- Piperacillin-tazobactam 4.5g (IV)\n- Cefoperazone-sulbactam 3g (IV)\n- Meropenem 1g (IV)\n\n**Alternative Options:**\n- Meropenem\n- Imipenem\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Febrile neutropenia syndrome", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What does ICMR recommend for treating Orthopaedic implant associated infections?", "response": "According to ICMR 2025 Guidelines for Orthopaedic implant associated infections:\n\n**First-Line Treatment:**\n- Debridement\n- Targeted antibiotic\n\n**Alternative Options:**\n- As in acute osteomyelitis\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Orthopaedic implant associated infections", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What does ICMR recommend for treating Community Acquired Pneumonia (CAP)?", "response": "According to ICMR 2025 Guidelines for Community Acquired Pneumonia (CAP):\n\n**First-Line Treatment:**\n- PIPERACILLIN-TAZOBACTAM 4.5g (IV) for 7 days\n- AZITHROMYCIN 500mg (PO) for 7 days\n- DOXYCYCLINE 100mg (PO) for 7 days\n\n**Alternative Options:**\n- IMIPENEM\n- MEROPENEM\n\n**Common Pathogens:** Streptococcus pneumoniae, Haemophilus influenzae\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Community Acquired Pneumonia (CAP)", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What antibiotics are recommended for Septic Abortion?", "response": "According to ICMR 2025 Guidelines for Septic Abortion:\n\n**First-Line Treatment:**\n- AMPICILLIN 2g (IV) for 7-10 days\n- GENTAMICIN 5 mg/kg (IV) for 7-10 days\n- METRONIDAZOLE 500 mg (IV) for 7-10 days\n\n**Alternative Options:**\n- CLINDAMYCIN\n- GENTAMICIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Septic Abortion", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "What are the indications for Oseltamivir?", "response": "**Oseltamivir** is used in the treatment of:\n\n- Rhinitis/Common cold\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Oseltamivir", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "Tell me about Eikenella corrodens treatment", "response": "**Eikenella corrodens** is commonly associated with:\n\n- Bite wound infections\n- Infective Endocarditis\n\n**Effective antibiotics include:**\n- Meropenem\n- Gentamicin\n- Amoxicillin-Clavulanic acid\n- Vancomycin\n- Ampicillin\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Eikenella corrodens", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What is the first-line treatment for Bite wound infections?", "response": "According to ICMR 2025 Guidelines for Bite wound infections:\n\n**First-Line Treatment:**\n- Amoxicillin-clavulanic acid 625mg (PO) for 3 to 5 days\n- Piperacillin-tazobactam 4.5g (IV) for 5 to 7 days\n- Valacyclovir/Acyclovir for 7 days\n\n**Alternative Options:**\n- Cefuroxime\n- Doxycycline\n\n**Common Pathogens:** Staphylococcus aureus, Pasteurella multocida, Anaerobes\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Bite wound infections", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "List the first-line drugs for Acute Prostatitis", "response": "According to ICMR 2025 Guidelines for Acute Prostatitis:\n\n**First-Line Treatment:**\n- CEFTRIAXONE 500mg (IM) for 10 days\n- DOXYCYCLINE 100mg (PO) for 10 days\n- CEFIXIME 800mg (PO) for 10 days\n\n**Alternative Options:**\n- CLINDAMYCIN\n- GENTAMICIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Acute Prostatitis", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "How do I treat Haemophilus influenzae infections?", "response": "**Haemophilus influenzae** is commonly associated with:\n\n- Bite wound infections\n- Community Acquired Pneumonia (CAP)\n\n**Effective antibiotics include:**\n- Amoxicillin-Clavulanic acid\n- AZITHROMYCIN\n- PIPERACILLIN-TAZOBACTAM\n- Amoxicillin-clavulanic acid\n- Valacyclovir/Acyclovir\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Haemophilus influenzae", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "Tell me about Ceftazidime-avibactam", "response": "**Ceftazidime-avibactam** is used in the treatment of:\n\n- Febrile neutropenia syndrome\n- Febrile neutropenia syndrome\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Ceftazidime-avibactam", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "Show me the treatment guidelines for Neonatal Infections", "response": "According to ICMR 2025 Guidelines for Neonatal Infections:\n\n**First-Line Treatment:**\n- PIPERACILLIN-TAZOBACTAM 15 mg/kg/dose (IV) for 5-7 days or 7-14 days\n- CIPROFLOXACIN 10 mg/kg/dose (IV) for 5-7 days or 7-14 days\n- CEFOTAXIME Not specified (Not specified) for 21 days\n\n**Alternative Options:**\n- TEICOPLANIN\n- AMPICILLIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Neonatal Infections", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "Show me the treatment guidelines for CSF shunt infections", "response": "According to ICMR 2025 Guidelines for CSF shunt infections:\n\n**First-Line Treatment:**\n- Vancomycin 25 mg/kg (IV)\n- Ceftazidime 2g (IV)\n- Cefepime 2g (IV)\n\n**Alternative Options:**\n- Vancomycin\n- Meropenem\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "CSF shunt infections", "source": "ICMR 2025"}
{"task_type": "education", "query": "What is the difference between first-line and alternative drugs?", "response": "**First-line drugs** are the preferred initial treatment options based on:\n- Proven efficacy\n- Safety profile\n- Cost-effectiveness\n- Local resistance patterns\n\n**Alternative drugs** are used when:\n- Patient has allergies to first-line agents\n- First-line therapy has failed\n- Culture results indicate resistance\n- Specific contraindications exist\n\nICMR guidelines provide both first-line and alternative options to guide rational antibiotic use.", "source": "AMR education"}
{"task_type": "syndrome_overview", "query": "What should I know about Healthcare Associated Infections?", "response": "# Healthcare Associated Infections\n\n**Definition:** Fever in ICU can be due to infective or non-infective causes. Empiric therapy for HAI would depend upon the infectious syndrome, organism prevalent in the unit, local resistance pattern.\n\n**Common Pathogens:**\n- C. glabrata\n- C. auris\n- C. krusei\n- E. coli\n- Pseudomonas spp.\n\n**First-Line Treatment (ICMR 2025):**\n- MICAFUNGIN 100 mg for Not specified\n- ANIDULAFUNGIN 200 mg loading dose, then 100 mg daily for Not specified\n- CASPOFUNGIN 70 mg loading dose, then 50 mg daily for Not specified\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Healthcare Associated Infections", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "What is PIPERACILLIN-TAZOBACTAM used for?", "response": "**PIPERACILLIN-TAZOBACTAM** is used in the treatment of:\n\n- Urinary Tract Infections\n- Septic Abortion\n- Acute Prostatitis\n- Community Acquired Pneumonia (CAP)\n- Healthcare Associated Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "PIPERACILLIN-TAZOBACTAM", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Tell me about Enteric fever", "response": "# Enteric fever\n\n**Definition:** Blood culture remains the gold standard.\n\n**First-Line Treatment (ICMR 2025):**\n- Azithromycin 20 mg /kg/day for 7 days\n- Cotrimoxazole 960 mg for 2 weeks\n- Ceftriaxone 2g for 10-14 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Enteric fever", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "What should I know about Diabetic foot infections (DFI)?", "response": "# Diabetic foot infections (DFI)\n\n**Definition:** Local infection with 0.5cm to < 2cm erythema\n\n**First-Line Treatment (ICMR 2025):**\n- Cloxacillin 500 mg for 1 to 2 weeks\n- Cephalexin 500 mg for 1 to 2 weeks\n- Cefadroxil 500 mg for 1 to 2 weeks\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Diabetic foot infections (DFI)", "source": "ICMR 2025"}
{"task_type": "education", "query": "What is antimicrobial stewardship?", "response": "Antimicrobial stewardship refers to coordinated interventions designed to improve and measure the appropriate use of antimicrobials by promoting the selection of the optimal antimicrobial drug regimen, dose, duration of therapy, and route of administration. Key principles include:\n\n- Using the right antibiotic for the right infection\n- Using narrow-spectrum agents when possible\n- Prescribing for appropriate durations\n- De-escalating therapy based on culture results\n- Avoiding antibiotics for viral infections\n\nThis helps prevent antimicrobial resistance and improves patient outcomes.", "source": "AMR education"}
{"task_type": "guideline_lookup", "query": "List the first-line drugs for Invasive Candidiasis", "response": "According to ICMR 2025 Guidelines for Invasive Candidiasis:\n\n**First-Line Treatment:**\n- Micafungin 100 mg (IV)\n- Anidulafungin 200 mg (IV)\n- Caspofungin 70 mg (IV)\n\n**Alternative Options:**\n- Liposomal Amphotericin B\n\n**Common Pathogens:** Candida albicans, C. glabrata, C. parapsilosis\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Invasive Candidiasis", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Explain Acute Undifferentiated Febrile illness treatment", "response": "# Acute Undifferentiated Febrile illness\n\n**Definition:** Acute febrile syndrome presents with headache, chills, or muscle and joint pains and is usually viral and often resolves without treatment. Acute febrile syndrome can also be caused by bacterial, rickettsial or parasitic infections and non-infective conditions like autoimmune disorders.\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Acute Undifferentiated Febrile illness", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "List the first-line drugs for Infective Endocarditis", "response": "According to ICMR 2025 Guidelines for Infective Endocarditis:\n\n**First-Line Treatment:**\n- Penicillin G 4 million units (IV) for 4 weeks\n- Ampicillin 2g (IV) for 4 weeks\n- Gentamicin 1mg/kg (IM or IV) for first 2 weeks\n\n**Alternative Options:**\n- Vancomycin\n- Gentamicin\n\n**Common Pathogens:** Staphylococcus aureus, Coagulase-negative Staphylococci, Enterococci\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Infective Endocarditis", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "Tell me about Amoxicillin-clavulanic Acid", "response": "**Amoxicillin-clavulanic Acid** is used in the treatment of:\n\n- Infections of Liver, Gall Bladder and Biliary tract\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Amoxicillin-clavulanic Acid", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What does ICMR recommend for treating Bite wound infections?", "response": "According to ICMR 2025 Guidelines for Bite wound infections:\n\n**First-Line Treatment:**\n- Amoxicillin-clavulanic acid 625mg (PO) for 3 to 5 days\n- Piperacillin-tazobactam 4.5g (IV) for 5 to 7 days\n- Valacyclovir/Acyclovir for 7 days\n\n**Alternative Options:**\n- Cefuroxime\n- Doxycycline\n\n**Common Pathogens:** Staphylococcus aureus, Pasteurella multocida, Anaerobes\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Bite wound infections", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "What is IMIPENEM-CILASTATIN used for?", "response": "**IMIPENEM-CILASTATIN** is used in the treatment of:\n\n- Tertiary Peritonitis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "IMIPENEM-CILASTATIN", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What does ICMR recommend for treating Possible serious bacterial infection, PSBI (community acquired)?", "response": "According to ICMR 2025 Guidelines for Possible serious bacterial infection, PSBI (community acquired):\n\n**First-Line Treatment:**\n- Amoxicillin 20-40 mg/kg/dose (PO)\n- Ampicillin 50 mg/kg/dose (IV)\n- Ampicillin 75 mg/kg/dose (IV)\n\n**Alternative Options:**\n- Ampicillin\n- Cefotaxime\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Possible serious bacterial infection, PSBI (community acquired)", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "Tell me about Cladophialophora treatment", "response": "**Cladophialophora** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Cladophialophora", "source": "ICMR 2025"}
{"task_type": "education", "query": "What is empirical antibiotic therapy?", "response": "Empirical antibiotic therapy is the initial treatment given before laboratory culture and sensitivity results are available. It is based on:\n\n1. **Clinical diagnosis** of the infection\n2. **Most likely pathogens** for that infection\n3. **Local resistance patterns**\n4. **Patient factors** (age, comorbidities, allergies)\n5. **Guideline recommendations** (like ICMR 2025)\n\n**Key principle**: Start broad-spectrum therapy, then de-escalate to narrow-spectrum based on culture results (de-escalation strategy).\n\nThis approach ensures timely treatment while minimizing unnecessary broad-spectrum use.", "source": "AMR education"}
{"task_type": "drug_information", "query": "When should I prescribe CASPOFUNGIN?", "response": "**CASPOFUNGIN** is used in the treatment of:\n\n- Healthcare Associated Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "CASPOFUNGIN", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "List the first-line drugs for Skin and Soft Tissue Infections", "response": "According to ICMR 2025 Guidelines for Skin and Soft Tissue Infections:\n\n**First-Line Treatment:**\n- AMOXICILLIN-CLAVULANATE 625mg (PO) for 3 to 7 days\n- AMOXICILLIN-CLAVULANIC ACID 1.2g (IV) for 3 to 7 days\n\n**Alternative Options:**\n- CEFUROXIME\n- CLINDAMYCIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Skin and Soft Tissue Infections", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "What antibiotics work against Nocardia?", "response": "**Nocardia** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Nocardia", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Tell me about Acute Undifferentiated Febrile illness", "response": "# Acute Undifferentiated Febrile illness\n\n**Definition:** Acute febrile syndrome presents with headache, chills, or muscle and joint pains and is usually viral and often resolves without treatment. Acute febrile syndrome can also be caused by bacterial, rickettsial or parasitic infections and non-infective conditions like autoimmune disorders.\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Acute Undifferentiated Febrile illness", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "What are the indications for Cephalexin?", "response": "**Cephalexin** is used in the treatment of:\n\n- Diabetic foot infections (DFI)\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Cephalexin", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Give me an overview of Community Acquired Pneumonia (CAP)", "response": "# Community Acquired Pneumonia (CAP)\n\n**Definition:** Pneumonia acquired outside of hospitals or other healthcare facilities\n\n**Common Pathogens:**\n- Streptococcus pneumoniae\n- Haemophilus influenzae\n\n**First-Line Treatment (ICMR 2025):**\n- PIPERACILLIN-TAZOBACTAM 4.5g for 7 days\n- AZITHROMYCIN 500mg for 7 days\n- DOXYCYCLINE 100mg for 7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Community Acquired Pneumonia (CAP)", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "What antibiotics work against Aeromonas hydrophila?", "response": "**Aeromonas hydrophila** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Aeromonas hydrophila", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "In which infections is Cefotaxime used?", "response": "**Cefotaxime** is used in the treatment of:\n\n- Meningitis syndrome\n- Community Acquired Pneumonia\n- Infections in Asplenia\n- Possible serious bacterial infection, PSBI (community acquired)\n- Neonatal Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Cefotaxime", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "Tell me about Capnocytophaga canimorsus treatment", "response": "**Capnocytophaga canimorsus** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Capnocytophaga canimorsus", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "When should I prescribe FOSCARNET?", "response": "**FOSCARNET** is used in the treatment of:\n\n- Orbital Cellulitis and Retinitis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "FOSCARNET", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "What antibiotics work against Listeria monocytogenes?", "response": "**Listeria monocytogenes** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Listeria monocytogenes", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "What is CLOTRIMAZOLE used for?", "response": "**CLOTRIMAZOLE** is used in the treatment of:\n\n- Oropharyngeal Candidiasis\n- Superficial Abscesses and Other Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "CLOTRIMAZOLE", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "List the first-line drugs for Bronchitis", "response": "According to ICMR 2025 Guidelines for Bronchitis:\n\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Bronchitis", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "List the first-line drugs for Febrile neutropenia syndrome", "response": "According to ICMR 2025 Guidelines for Febrile neutropenia syndrome:\n\n**First-Line Treatment:**\n- Piperacillin-tazobactam 4.5g (IV)\n- Cefoperazone-sulbactam 3g (IV)\n- Meropenem 1g (IV)\n\n**Alternative Options:**\n- Meropenem\n- Imipenem\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Febrile neutropenia syndrome", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What is the first-line treatment for Community Acquired Pneumonia?", "response": "According to ICMR 2025 Guidelines for Community Acquired Pneumonia:\n\n**First-Line Treatment:**\n- Amoxicillin 1g (PO) for 5-7 days\n- Amoxicillin-clavulanate 1g (PO) for 5-7 days\n- Ceftriaxone 2g (IV) for 5-7 days\n\n**Alternative Options:**\n- Azithromycin\n- Clarithromycin\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Community Acquired Pneumonia", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "Show me the treatment guidelines for Periocular infections (Eyelid infections, Orbital cellulitis)", "response": "According to ICMR 2025 Guidelines for Periocular infections (Eyelid infections, Orbital cellulitis):\n\n**First-Line Treatment:**\n- AMOXICILLIN 90/6.4 mg/kg/day (PO) for 5-7 days\n- COTRIMOXAZOLE 5 mg/kg per day (PO) for 5 to 7 days\n- CLINDAMYCIN 10mg/kg/dose (max 600 mg/dose) (PO) for 5 to 7 days\n\n**Alternative Options:**\n- CLINDAMYCIN\n- TRIMETHOPRIM-SULFAMETHOXAZOLE\n\n**Common Pathogens:** Streptococcus pneumoniae, Hemophilus influenzae, Staphylococcus aureus\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Periocular infections (Eyelid infections, Orbital cellulitis)", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "Show me the treatment guidelines for Invasive Candidiasis", "response": "According to ICMR 2025 Guidelines for Invasive Candidiasis:\n\n**First-Line Treatment:**\n- Micafungin 100 mg (IV)\n- Anidulafungin 200 mg (IV)\n- Caspofungin 70 mg (IV)\n\n**Alternative Options:**\n- Liposomal Amphotericin B\n\n**Common Pathogens:** Candida albicans, C. glabrata, C. parapsilosis\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Invasive Candidiasis", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Explain Possible serious bacterial infection, PSBI (community acquired) treatment", "response": "# Possible serious bacterial infection, PSBI (community acquired)\n\n**Definition:** Consider PSBI if any one of the following signs is present:\n•\tNot able to feed since birth or stopped feeding well (confirmed by observation)\n•\tNo movement or movement only on stimulation\n•\tConvulsions\n•\tFast breathing (60 breaths per minute or more) in infants younger than 7 days of age\n•\tSevere chest in-drawing\n•\tFever (≥ 38.0 °C)\n•\tLow body temperature (< 35.5 °C)\nSigns are nonspecific.\n\n**First-Line Treatment (ICMR 2025):**\n- Amoxicillin 20-40 mg/kg/dose\n- Ampicillin 50 mg/kg/dose\n- Ampicillin 75 mg/kg/dose\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Possible serious bacterial infection, PSBI (community acquired)", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "What is LIPosomal AMphotericin B used for?", "response": "**LIPosomal AMphotericin B** is used in the treatment of:\n\n- Healthcare Associated Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "LIPosomal AMphotericin B", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Give me an overview of Infections in Asplenia", "response": "# Infections in Asplenia\n\n**Definition:** null\n\n**First-Line Treatment (ICMR 2025):**\n- Ceftriaxone 2g for 7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Infections in Asplenia", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "Show me the treatment guidelines for Rhinitis/Common cold", "response": "According to ICMR 2025 Guidelines for Rhinitis/Common cold:\n\n**First-Line Treatment:**\n- paracetamol\n- Oseltamivir 75mg for 5-7 days\n\n**Alternative Options:**\n- decongestants\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Rhinitis/Common cold", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Explain Bronchitis treatment", "response": "# Bronchitis\n\n**Definition:** Bronchitis\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Bronchitis", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What does ICMR recommend for treating Acute Osteomyelitis?", "response": "According to ICMR 2025 Guidelines for Acute Osteomyelitis:\n\n**First-Line Treatment:**\n- Cloxacillin 2g (IV)\n\n**Alternative Options:**\n- Amoxicillin-clavulanic acid\n- Cefazolin\n\n**Common Pathogens:** Staphylococcus aureus, Streptococci, Escherichia coli\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Acute Osteomyelitis", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "What are the indications for CIPROFLOXACIN?", "response": "**CIPROFLOXACIN** is used in the treatment of:\n\n- Periocular infections (Eyelid infections, Orbital cellulitis)\n- Neonatal Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "CIPROFLOXACIN", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "Show me the treatment guidelines for Antibiotic Associated Diarrhoea", "response": "According to ICMR 2025 Guidelines for Antibiotic Associated Diarrhoea:\n\n**First-Line Treatment:**\n- VANCOMYCIN 125mg (PO) for Not specified\n- METRONIDAZOLE 500mg (IV) for Not specified\n\n**Common Pathogens:** Clostridium difficile\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Antibiotic Associated Diarrhoea", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "In which infections is LIPosomal AMphotericin B used?", "response": "**LIPosomal AMphotericin B** is used in the treatment of:\n\n- Healthcare Associated Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "LIPosomal AMphotericin B", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "Tell me about Aspergillus treatment", "response": "**Aspergillus** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Aspergillus", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "When should I prescribe Cloxacillin?", "response": "**Cloxacillin** is used in the treatment of:\n\n- Diabetic foot infections (DFI)\n- Acute Osteomyelitis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Cloxacillin", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What does ICMR recommend for treating Antimicrobial Treatment Guidelines?", "response": "According to ICMR 2025 Guidelines for Antimicrobial Treatment Guidelines:\n\n**First-Line Treatment:**\n- MEROPENEM 1g (IV) for Not specified\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Antimicrobial Treatment Guidelines", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What does ICMR recommend for treating Febrile neutropenia syndrome?", "response": "According to ICMR 2025 Guidelines for Febrile neutropenia syndrome:\n\n**First-Line Treatment:**\n- Piperacillin-tazobactam 4.5g (IV)\n- Cefoperazone-sulbactam 3g (IV)\n- Meropenem 1g (IV)\n\n**Alternative Options:**\n- Meropenem\n- Imipenem\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Febrile neutropenia syndrome", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "What is Amoxicillin used for?", "response": "**Amoxicillin** is used in the treatment of:\n\n- Community Acquired Pneumonia\n- Possible serious bacterial infection, PSBI (community acquired)\n- Neonatal Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Amoxicillin", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What does ICMR recommend for treating Infections of Liver, Gall Bladder and Biliary tract?", "response": "According to ICMR 2025 Guidelines for Infections of Liver, Gall Bladder and Biliary tract:\n\n**First-Line Treatment:**\n- Metronidazole 750mg (IV or oral) for total 10 days\n- Ceftriaxone 2g (IV)\n- Metronidazole 750mg (q8h)\n\n**Alternative Options:**\n- Tinidazole\n- Piperacillin-tazobactam\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Infections of Liver, Gall Bladder and Biliary tract", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "Tell me about Mucor treatment", "response": "**Mucor** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Mucor", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "Tell me about Streptobacillus moniliformis treatment", "response": "**Streptobacillus moniliformis** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Streptobacillus moniliformis", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "Tell me about Streptococci treatment", "response": "**Streptococci** is commonly associated with:\n\n- Acute Osteomyelitis\n\n**Effective antibiotics include:**\n- Cloxacillin\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Streptococci", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "Tell me about HSV treatment", "response": "**HSV** is commonly associated with:\n\n- Gastro-intestinal (GI) Syndromes - Oesophagitis\n- Conjunctivitis\n\n**Effective antibiotics include:**\n- TRIFLURIDINE\n- ACYCLOVIR\n- GENTAMICIN\n- FLUCONAZOLE\n- GANCICLOVIR\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "HSV", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What does ICMR recommend for treating Bite wound infections?", "response": "According to ICMR 2025 Guidelines for Bite wound infections:\n\n**First-Line Treatment:**\n- Amoxicillin-clavulanic acid 625mg (PO) for 3 to 5 days\n- Piperacillin-tazobactam 4.5g (IV) for 5 to 7 days\n- Valacyclovir/Acyclovir for 7 days\n\n**Alternative Options:**\n- Cefuroxime\n- Doxycycline\n\n**Common Pathogens:** Staphylococcus aureus, Pasteurella multocida, Anaerobes\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Bite wound infections", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Give me an overview of Oropharyngeal Candidiasis", "response": "# Oropharyngeal Candidiasis\n\n**Definition:** Common local infection seen in infants, older adults who wear dentures, patients treated with antibiotics, chemotherapy or radiation therapy to the head and neck, and those with cellular immune deficiency like HIV.\n\n**First-Line Treatment (ICMR 2025):**\n- CLOTRIMAZOLE 10mg for 7 days\n- FLUCONAZOLE 200mg for 7-14 days\n- FLUCONAZOLE 100-150mg (3mg/kg for children) for 7-14 days\n\n**Special Populations:** Consider dose adjustments or alternative agents\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Oropharyngeal Candidiasis", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "How do I treat Entamoeba histolytica infections?", "response": "**Entamoeba histolytica** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Entamoeba histolytica", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "What antibiotics work against Candida?", "response": "**Candida** is commonly associated with:\n\n- Brain Abscess\n- Gastro-intestinal (GI) Syndromes - Oesophagitis\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- FLUCONAZOLE\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Candida", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "What antibiotics work against Cytomegalovirus?", "response": "**Cytomegalovirus** is commonly associated with:\n\n- Orbital Cellulitis and Retinitis\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- VANCOMYCIN\n- GANCICLOVIR\n- VALGANCICLOVIR\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Cytomegalovirus", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "What antibiotics work against Leptospira spp.?", "response": "**Leptospira spp.** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Leptospira spp.", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "What is ITRACONAZOLE used for?", "response": "**ITRACONAZOLE** is used in the treatment of:\n\n- Gastro-intestinal (GI) Syndromes - Oesophagitis\n- Oropharyngeal Candidiasis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "ITRACONAZOLE", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "Tell me about Hemophilus influenzae treatment", "response": "**Hemophilus influenzae** is commonly associated with:\n\n- Periocular infections (Eyelid infections, Orbital cellulitis)\n\n**Effective antibiotics include:**\n- AMOXICILLIN-CLAVULANATE\n- CEFTRIAXONE\n- AMOXICILLIN\n- CLINDAMYCIN\n- COTRIMOXAZOLE\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Hemophilus influenzae", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "Tell me about Aztreonam", "response": "**Aztreonam** is used in the treatment of:\n\n- CSF shunt infections\n- Febrile neutropenia syndrome\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Aztreonam", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "How do I treat Anaerobes infections?", "response": "**Anaerobes** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Anaerobes", "source": "ICMR 2025"}
{"task_type": "education", "query": "What are ESBL-producing bacteria?", "response": "ESBL (Extended-Spectrum Beta-Lactamase) producing bacteria are organisms that produce enzymes capable of breaking down many common antibiotics, including:\n\n- Penicillins\n- Most cephalosporins\n- Aztreonam\n\n**Common ESBL producers:**\n- E. coli\n- Klebsiella species\n- Proteus mirabilis\n\n**Treatment options:**\n- Carbapenems (e.g., Meropenem, Imipenem)\n- Piperacillin-Tazobactam (for less severe infections)\n- Some fluoroquinolones (based on susceptibility)\n\nESBL infections require culture-guided therapy and strict infection control measures.", "source": "AMR education"}
{"task_type": "pathogen_treatment", "query": "Tell me about Pasteurella multocida treatment", "response": "**Pasteurella multocida** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Pasteurella multocida", "source": "ICMR 2025"}
{"task_type": "drug_information", "query": "Tell me about Silver nitrate", "response": "**Silver nitrate** is used in the treatment of:\n\n- Burn wound infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "drug": "Silver nitrate", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "Tell me about CMV treatment", "response": "**CMV** is commonly associated with:\n\n- Gastro-intestinal (GI) Syndromes - Oesophagitis\n- Conjunctivitis\n\n**Effective antibiotics include:**\n- TRIFLURIDINE\n- ACYCLOVIR\n- GENTAMICIN\n- FLUCONAZOLE\n- GANCICLOVIR\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "CMV", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Tell me about Botulism", "response": "# Botulism\n\n**Definition:** Botulism is a serious medical emergency that requires immediate treatment. Botulinum antitoxins to be administered as soon as possible, this can neutralize botulinum toxin and prevent further damage.\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Botulism", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What does ICMR recommend for treating Enteric fever?", "response": "According to ICMR 2025 Guidelines for Enteric fever:\n\n**First-Line Treatment:**\n- Azithromycin 20 mg /kg/day for 7 days\n- Cotrimoxazole 960 mg for 2 weeks\n- Ceftriaxone 2g (IV) for 10-14 days\n\n**Alternative Options:**\n- Cefixime\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Enteric fever", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "What should I know about Septic Abortion?", "response": "# Septic Abortion\n\n**Definition:** Fever, Vaginal discharge, pelvic/abdominal pain, etc. Symptoms usually appear within 24 to 48 hours after an abortion.\n\n**First-Line Treatment (ICMR 2025):**\n- AMPICILLIN 2g for 7-10 days\n- GENTAMICIN 5 mg/kg for 7-10 days\n- METRONIDAZOLE 500 mg for 7-10 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Septic Abortion", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What is the first-line treatment for Burn wound infections?", "response": "According to ICMR 2025 Guidelines for Burn wound infections:\n\n**First-Line Treatment:**\n- Silver sulfadiazine 1% (Topical)\n- Silver nitrate 0.5% (Topical)\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Burn wound infections", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What is the first-line treatment for Septic Abortion?", "response": "According to ICMR 2025 Guidelines for Septic Abortion:\n\n**First-Line Treatment:**\n- AMPICILLIN 2g (IV) for 7-10 days\n- GENTAMICIN 5 mg/kg (IV) for 7-10 days\n- METRONIDAZOLE 500 mg (IV) for 7-10 days\n\n**Alternative Options:**\n- CLINDAMYCIN\n- GENTAMICIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Septic Abortion", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What antibiotics are recommended for Dental Infections?", "response": "According to ICMR 2025 Guidelines for Dental Infections:\n\n**First-Line Treatment:**\n- METRONIDAZOLE 400mg (PO) for 5 days\n- AMOXICILLIN 1g (PO) for Not specified\n- METRONIDAZOLE 400mg (PO) for Not specified\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Dental Infections", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "List the first-line drugs for Tertiary Peritonitis", "response": "According to ICMR 2025 Guidelines for Tertiary Peritonitis:\n\n**First-Line Treatment:**\n- IMIPENEM-CILASTATIN 500 mg (IV) for 5-7 days\n- MEROPENEM 1g (IV) for 5-7 days\n\n**Alternative Options:**\n- POLYMYXIN B\n- COLISTIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Tertiary Peritonitis", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "What does ICMR recommend for treating Healthcare Associated Infections?", "response": "According to ICMR 2025 Guidelines for Healthcare Associated Infections:\n\n**First-Line Treatment:**\n- MICAFUNGIN 100 mg (IV) for Not specified\n- ANIDULAFUNGIN 200 mg loading dose, then 100 mg daily (IV) for Not specified\n- CASPOFUNGIN 70 mg loading dose, then 50 mg daily (IV) for Not specified\n\n**Alternative Options:**\n- POLYMYXIN B\n- COLISTIN\n\n**Common Pathogens:** C. glabrata, C. auris, C. krusei\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Healthcare Associated Infections", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "List the first-line drugs for Urinary Tract Infections", "response": "According to ICMR 2025 Guidelines for Urinary Tract Infections:\n\n**First-Line Treatment:**\n- NITROFURANTOIN 100 mg (PO) for 5 days\n- PIPERACILLIN-TAZOBACTAM 4.5g (IV) for 7-10 days\n\n**Alternative Options:**\n- COTRIMOXAZOLE\n- ERTAPENEM\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Urinary Tract Infections", "source": "ICMR 2025"}
{"task_type": "syndrome_overview", "query": "Give me an overview of Acute Undifferentiated Febrile illness", "response": "# Acute Undifferentiated Febrile illness\n\n**Definition:** Acute febrile syndrome presents with headache, chills, or muscle and joint pains and is usually viral and often resolves without treatment. Acute febrile syndrome can also be caused by bacterial, rickettsial or parasitic infections and non-infective conditions like autoimmune disorders.\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Acute Undifferentiated Febrile illness", "source": "ICMR 2025"}
{"task_type": "pathogen_treatment", "query": "What antibiotics work against Cryptococcus neoformans?", "response": "**Cryptococcus neoformans** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "pathogen": "Cryptococcus neoformans", "source": "ICMR 2025"}
{"task_type": "guideline_lookup", "query": "Show me the treatment guidelines for Septic Abortion", "response": "According to ICMR 2025 Guidelines for Septic Abortion:\n\n**First-Line Treatment:**\n- AMPICILLIN 2g (IV) for 7-10 days\n- GENTAMICIN 5 mg/kg (IV) for 7-10 days\n- METRONIDAZOLE 500 mg (IV) for 7-10 days\n\n**Alternative Options:**\n- CLINDAMYCIN\n- GENTAMICIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "syndrome": "Septic Abortion", "source": "ICMR 2025"}
